System | Condition | Evidence base |
Central nervous system | Acute pain | l Perioperative IV magnesium reduced opiate consumption postoperatively and led to reduced pain scores [46] |
| Chronic pain | l IV and PO magnesium increased range of movement and reduced pain scores in chronic back pain with a neuropathic component [48] |
| Memory dysfunction | l Increased brain magnesium enhanced learning and memory in rats [72] but no research in humans to date |
| Neuromuscular blockade | l Potentiates the effects of non-depolarising neuromuscular blocking agents [73] - [76] l Blunts the serum potassium rise induced by suxamethonium [77] |
| Postoperative shivering and thermoregulation | l Reduction in hypothermic shivering threshold from 36.6˚C to 36.3˚C (not clinically significant) [78] , some reports of reduced postoperative shivering [79] - [81] but not borne out in a systematic review [82] |
| Insomnia | l PO supplementation gave improved sleep quality, sleep time and ease of getting to sleep [49] |
Cardiovascular system | Arrhythmias | l Treatment for torsades de pointes, digoxin toxicity, most atrial and ventricular arrhythmias where hypokalaemia is present [50] l Superior to amiodarone in cardioversion of atrial tachyarrhythmias in intensive care [51] |
| Myocardial infarction | l Reduced infarct size in canine model [83] l LIMIT-2 study showed reduced 28-day mortality in magnesium treated group [84] l Larger and more recent ISIS-4 and MAGIC-2 trials showed no survival benefit [85] [86] |
| Cardiothoracic surgery | l Prophylactic magnesium reduced incidence of postoperative atrial fibrillation from 28% to 18% [53] and ventricular arrhythmias by 48% [54] l Magnesium in cardioplegic solution reduced postoperative ischaemia [55] |
| Phaeochromocytoma anaesthesia | l Case series reported 15 out of 17 cases with good haemodynamic stability at induction and tracheal intubation, with 4 cases requiring additional pharmacological support for blood pressure control during tumour handling [59] |
Respiratory system | Acute severe asthma | l Scottish Intercollegiate Guidelines Network (SIGN) and British Thoracic Society (BTS) 2012 recommend intravenous magnesium for patients with acute asthma, non-respondent to inhaled short-acting beta-2 agonists, inhaled anticholinergics, corticosteroids and oxygen [60] l Reduced admission rates in acute severe asthma but not in non-severe [61] |
| Respiratory muscle weakness | l Improved respiratory muscle power in hypomagnesaemic patients given supplementation [62] |
Gastrointestinal system | Mendelson’s syndrome | l Magnesium trisillicate is superior to cimetidine in achieving a higher gastric pH [66] in prophylaxis against Mendelson’s syndrome (pulmonary aspiration of gastric contents in obstetric anaesthesia) |
Obstetrics | Eclampsia | l Reduced risk of maternal death and seizure recurrence compared to diazepam [67] |
| Pre-eclampsia | l Reduced risk of developing eclampsia compared to placebo, phenytoin and nimodipine [68] |